Dyne Therapeutics Inc - Asset Resilience Ratio

Latest as of March 2026: 20.28%

Dyne Therapeutics Inc (DYN) has an Asset Resilience Ratio of 20.28% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

$219.05 Million
Cash + Short-term Investments

Total Assets

$1.08 Billion
All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2007–2025)

This chart shows how Dyne Therapeutics Inc's Asset Resilience Ratio has changed over time. Check DYN PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Dyne Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Dyne Therapeutics Inc market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $219.05 Million 20.28%
Total Liquid Assets $219.05 Million 20.28%

Asset Resilience Insights

  • Good Liquidity Position: Dyne Therapeutics Inc maintains a healthy 20.28% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Dyne Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Dyne Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Akero Therapeutics Inc
NASDAQ:AKRO
Biotechnology 55.87%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Zealand Pharma A/S
CO:ZEAL
Biotechnology 63.98%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
Immunitybio Inc
NASDAQ:IBRX
Biotechnology 38.07%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

Annual Asset Resilience Ratio for Dyne Therapeutics Inc (2007–2025)

The table below shows the annual Asset Resilience Ratio data for Dyne Therapeutics Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 18.30% $217.19 Million $1.19 Billion -11.62pp
2024-12-31 29.92% $206.82 Million $691.23 Million +29.03pp
2023-12-31 0.89% $1.47 Million $165.08 Million -26.48pp
2022-12-31 27.38% $83.86 Million $306.32 Million -13.91pp
2021-12-31 41.29% $175.75 Million $425.66 Million +28.70pp
2020-12-31 12.58% $44.46 Million $353.33 Million +12.31pp
2017-12-31 0.27% $32.00 Million $11.77 Billion -0.72pp
2016-12-31 1.00% $130.00 Million $13.05 Billion +0.13pp
2015-12-31 0.87% $100.00 Million $11.54 Billion +0.17pp
2014-12-31 0.69% $78.00 Million $11.23 Billion +0.22pp
2013-12-31 0.47% $25.00 Million $5.29 Billion +0.19pp
2012-12-31 0.29% $13.00 Million $4.54 Billion -1.39pp
2011-12-31 1.67% $69.00 Million $4.13 Billion +0.61pp
2010-12-31 1.06% $106.00 Million $10.01 Billion +0.35pp
2009-12-31 0.71% $78.00 Million $10.95 Billion +0.10pp
2008-12-31 0.61% $87.00 Million $14.21 Billion -0.17pp
2007-12-31 0.79% $104.00 Million $13.22 Billion --
pp = percentage points

About Dyne Therapeutics Inc

NASDAQ:DYN USA Biotechnology
Market Cap
$4.16 Billion
Market Cap Rank
#4056 Global
#1409 in USA
Share Price
$25.18
Change (1 day)
-2.14%
52-Week Range
$10.25 - $25.90
All Time High
$47.04
About

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal mus… Read more